Alternatively, we have previously demonstrated that DCN expression degraded aberrant tumor ECM, which functions as a physical barrier to the dispersion and penetration of therapeutic Ads, by attenuating TGF-β expression levels [19]. This evidence concerns the gene TGFB1 and neoplasm.